Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile

@article{Ringe2012ImprovedRA,
  title={Improved real-life adherence of 6-monthly denosumab injections due to positive feedback based on rapid 6-month BMD increase and good safety profile},
  author={Johann Diederich Ringe and Parvis Farahmand},
  journal={Rheumatology International},
  year={2012},
  volume={34},
  pages={727-732}
}
Almost 50 % of osteoporosis (OP) patients discontinue bisphosphonate (BP) therapy within 1–2 years after the start of their treatment. Denosumab’s longer dosing interval with its administration every 6 months (Q6M) as a subcutaneous (sc) injection might result in a better real-life treatment adherence and persistence than weekly or monthly oral BP treatment regimen. The objectives of this open, investigator-initiated, prospective, observational, single-center study were to evaluate adherence… CONTINUE READING

From This Paper

Figures, tables, and topics from this paper.

Citations

Publications citing this paper.
Showing 1-7 of 7 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Analysis of the costs and consequences of adherence to therapy in hip fracture patients. Results of a longitudinal analysis of administrative databases

  • U Tarantino
  • Clin Cases Miner Bone Metab
  • 2011
2 Excerpts

Comparison of the effect of denosumab and alendronate on BMD and biochemical markers of bone turnover in postmenopausal women with low bone mass: a randomized, blinded, phase 3 trial

  • JP Brown
  • J Bone Miner Res
  • 2009
1 Excerpt

Similar Papers

Loading similar papers…